ミッドキャップバイオテクノロジー企業ベンチマークレポート...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 16
2 Introduction 18
2.1 Report Scope 18
2.2 Report Catalysts 20
2.3 Upcoming Related Reports 20
2.4 Recently Published Reports 21
2.5 GlobalData’s Benchmarking Methodology 21
2.6 GlobalData 3Q12 Biotech Benchmark Leader: Regeneron 22
2.7 Regeneron Overtook Alexion in 3Q12 as Benchmark Leader 23
3 Financial Management 25
3.1 Competitive Framework 25
3.2 Overview 26
3.2.1 Biotech companies position themselves for revenue growth with higher sales, but will need to focus on cost containment to improve profit margins 26
3.3 Financial Management: Heat Map 28
3.3.1 Regeneron was the financial management leader in 3Q12, posting significantly higher scores across all metrics compared to its peer group 28
3.4 Financial Metrics 29
3.4.1 Revenue 29
3.4.2 Revenue Growth YtY 30
3.4.3 Operating Income 31
3.4.4 Operating Income Growth YtY 32
3.4.5 Operating Margin 33
3.5 Expense Management: Heat Map 34
3.5.1 ViroPharma was the expense management leader in 3Q12 due to manufacturing issues 34
3.6 Expense Metrics 35
3.6.1 R&D Expense as a Percentage of Revenue 35
3.6.2 R&D Spend Growth YtY 36
3.6.3 S,G&A Expenses as a Percentage of Revenue 37
3.6.4 S,G&A Spend Growth YtY 38
3.6.5 Total OpEx as a Percentage of Revenue 39
4 Pipeline Assessment 40
4.1 Overview 40
4.1.1 Despite its high cost, biotech companies are still investing in oncology 40
4.1.2 Big Pharma’s exit from CNS creates an opportunity for smaller players 40
4.2 GlobalData Pipeline Matrix and Competitive Positioning 42
4.2.1 Quadrant Analysis: Best-In-Class Assessment: Regeneron 44
4.2.2 Quadrant Analysis: Challengers Assessment: Jazz 44
4.2.3 Quadrant Analysis: Laggards Assessment: Exelixis 45
4.2.4 Quadrant Analysis: Innovators Assessment: Momenta 45
4.3 Pipeline Development 46
4.4 Clinical Highlights by Company 48
4.4.1 Acorda 48
4.4.2 Alexion 49
4.4.3 Alkermes 49
4.4.4 BioMarin 50
4.4.5 Cubist 51
4.4.6 Exelixis 52
4.4.7 Incyte 53
4.4.8 Jazz 54
4.4.9 Momenta 54
4.4.10 Nektar 55
4.4.11 Onyx 56
4.4.12 Regeneron 57
4.4.13 Seattle 59
4.4.14 United 60
4.4.15 ViroPharma 61
5 Licensing & Acquisition Strategies 62
5.1 Competitive Framework 62
5.2 Overview 63
5.3 M&A Analysis 65
5.3.1 Alkermes Acquisition of Elan Drug Technology Creates Leadership in CNS Therapeutics 65
5.3.2 Jazz Acquisition of EUSA Pharma Expands its Product Line to Include High-Margin Cancer Therapies 66
5.3.3 Alexion Adds to its Ultra-Rare Disease Portfolio through Acquisition 67
5.3.4 Jazz Purchase of Azur Complements its Pipeline in CNS and Women’s Health 68
6 Resource Management Strategies 71
6.1 Competitive Framework 71
6.2 Overview 72
6.3 Operations & Supply Chain 73
6.3.1 Acorda Relocates Corporate HQ to Ardsley Park Life Sciences Campus 73
6.3.2 Cubist Expands Research & Development Facility 73
6.3.3 Jazz Sells Women’s Health Business to Meda 73
6.3.4 Nektar Consolidates Research Assets to its R&D Center in San Francisco, CA 74
6.3.5 Regeneron Expands Greenbush Plant to Support its Antibody Clinic 74
6.3.6 ViroPharma Adds Manufacturing Scale to Cinryze Production to Meet Expected Demand 74
6.4 Resource Management: Heat Map 75
6.4.1 Cubist was the resource management leader in 3Q12, balancing spending & headcount with revenue growth 75
6.5 Firm Utilization Metrics 76
6.5.1 Headcount Growth YtY 76
6.5.2 Revenue per Employee 77
6.5.3 SG&A Expense per SG&A Employee 78
6.5.4 R&D Expense per R&D Employee 79
6.6 Human Capital Leadership Changes 80
6.6.1 Successfully Implement Commercialization Strategies by Retaining Top Talent 80
6.7 Capital Management: Heat Map 81
6.7.1 Momenta was the Capital Management Leader in 3Q12 Keeping its Operating Leverage Lower Compared to its Peer Group 81
6.8 Capital Structure Metrics 82
6.8.1 Debt/Asset Ratio 82
6.8.2 Quick Ratio 83
6.8.3 Cash Ratio 84
6.8.4 Return-on-Investment Ratio 85
6.8.5 Sales/Assets Ratio 86
6.9 Share Offerings & Debt Restructurings 87
6.9.1 Share Repurchases Increase Working Capital and Provide Cash Flow to Reinvest Back into Internal R&D Programs 87
7 Company Drill-Downs & Forecasts 88
7.1 Acorda SWOT & Forecast 88
7.1.1 With Revenue Flattening, Acorda Looks to Extend Ampyra Labeling to Include Additional Indications and More Regions in the EU 88
7.2 Alexion SWOT & Forecast 90
7.2.1 Alexion Supplements its Orphan Drug Strategy with Bolt-on Acquisitions 90
7.3 Alkermes SWOT & Forecast 92
7.3.1 Alkermes is Well Positioned for Strong Revenue Generation as the Company Focuses on Commercializing Internal CNS Drug Candidates 92
7.4 BioMarin SWOT & Forecast 94
7.4.1 BioMarin Will Treat PKU Patients Across Their Entire Lifespan with PEG-PAL for Adults 94
7.5 Cubist SWOT & Forecast 96
7.5.1 Revenue Growth Driven by Higher-than-Expected Sales of Cubicin – Cubist Could Take Share from ViroPharma with CB-315 Drug Candidate 96
7.6 Exelixis SWOT & Forecast 98
7.6.1 Exelixis’ Revenue will Remain Flat Until it Maximizes the Commercial Potential of Cabozantinib for Multiple Oncology Indications 98
7.7 Incyte SWOT & Forecast 100
7.7.1 First-in-Class Jakafi Will Capture a Significant Share of the Myelofibrosis Market 100
7.8 Jazz SWOT & Forecast 102
7.8.1 Jazz’s Revenue Grew through Bolt-on Acquisitions – Higher Margin Cancer Therapies Complement Sales Growth of Xyrem 102
7.9 Momenta SWOT & Forecast 104
7.9.1 While Momenta is Feeling Pressure on its Top-Line, the Company is Poised to Capitalize on Opportunities with Heparin Candidates and Biologics 104
7.10 Nektar SWOT & Forecast 108
7.10.1 Nektar Will Continue to Invest Internally on Novel Cancer Therapies While Sub-licensing its PEGylation Technology to Supplement Revenue Growth 108
7.11 Onyx SWOT & Forecast 112
7.11.1 The Approval of Kyprolis Contributed to Organic Sales for Onyx; However, the Company’s High Cost Structure Erodes any Profitability 112
7.12 Regeneron SWOT & Forecast 115
7.12.1 Regeneron Posts its First Profitable Full-Year in History – Eylea Success Continues to Drive Top-line Growth, Clinical Pipeline is Buzzing 115
7.13 Seattle SWOT & Revenue Forecast 118
7.13.1 As Revenue Peaks, Seattle Expands Adcetris Availability to Outside the US, and Gets Creative with Diagnostic Partnership 118
7.14 United SWOT & Forecast 121
7.14.1 United Will Press Forward with a Plan to Develop an Oral Version of Remodulin, as the PAH Landscape Becomes More Complex 121
7.15 ViroPharma SWOT & Forecast 124
7.15.1 ViroPharma Experienced Significant Erosion from Generic Vancocin; the Company will Now Have to Rely Entirely on Cinryze for Profitability 124
7.16 GlobalData Forecast Summary 127
7.16.1 GlobalData Forecasts vs. Company Reported 3Q12 Results 127
8 Appendix 129
8.1 Research Methodology 129
8.1.1 Coverage 129
8.1.2 Secondary Research 129
8.1.3 Expert Panel Validation 130
8.2 About the Authors 131
8.2.1 Analysts 131
8.3 Director, Healthcare Industry Dynamics 132
8.4 GlobalHead of Healthcare Research & Consulting 132
8.5 About the Industry Dynamics Team 133
8.6 GlobalData 134
8.7 Contact Us 134
8.8 Disclosure Information 134
8.9 Disclaimer 135